1887

Journal of General Virology header logo

Volume 99, Issue 9

iPS cell serves as a source of dendritic cells for in vitro dengue virus infection model Free

Abstract

The lack of an appropriate model has been a serious concern in dengue research pertinent to immune response and vaccine development. It remains a matter of impediment in dengue virus (DENV) studies when it comes to an in vitro model, which requires adequate quantity of dendritic cells (DC) with uniform characters. Other sources of DC, mostly monocyte derived DC (moDC), have been used despite their limitations such as quantity, proliferation, and donor dependent characters. Recent development of human iPS cells with consistent proliferation for long, stable, functional characteristics and desired HLA background has certainly offered added advantages. Therefore, we hypothesised that iPS derived cells would be a reliable alternative to the traditional DCs to be used with an in vitro DENV system. To develop a DENV infection and T cell activation model, we utilised iPS cells (HLA-A*24) as the source of DC. iPS-ML-DC was prepared and DENV infectivity was assessed apart from the major surface markers expression and cytokine production potential. Our iPS-ML-DC had major DC markers expression, DENV infection efficiency and cytokine production properties similar to that of moDC. Moreover, DENV infected iPS-ML-DC demonstrated the ability to activate HLA-matched T cell (but not mismatched) in vitro as evidenced by significantly higher proportion of IFN-γ CD69 T cells compared to non-infected iPS-ML-DC. This affirmed the antigen-specific T cell activation by iPS-ML-DC as a function of antigen presenting cells. To conclude, maturation potential, DENV infection efficiency and T cell activation ability collectively suggest that iPS-ML-DC serves as an attractive option of DC for use in DENV studies in vitro.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antigen presentation , cellular immunity , dendritic cell , dengue virus , in vitro model and iPS cell
© 2018 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001119
2018-07-30
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/9/1239.html?itemId=/content/journal/jgv/10.1099/jgv.0.001119&mimeType=html&fmt=ahah

References

  1. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers 2016; 2:16055 [View Article][PubMed]
     [Google Scholar]
  2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW et al. The global distribution and burden of dengue. Nature 2013; 496:504–507 [View Article][PubMed]
     [Google Scholar]
  3. WHO Dengue guidelines for diagnosis, treatment, prevention and control: new edition; 2009 www.who.int/tdr/publications/documents/dengue-diagnosis.pdf
  4. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8:S7–S16 [View Article][PubMed]
     [Google Scholar]
  5. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2–9 [View Article][PubMed]
     [Google Scholar]
  6. Guzman MG, Harris E. Dengue. The Lancet 2015; 385:453–465 [View Article]
     [Google Scholar]
  7. Aguiar M, Stollenwerk N, Halstead SB. The impact of the newly licensed dengue vaccine in endemic countries. PLoS Negl Trop Dis 2016; 10:e0005179 [View Article][PubMed]
     [Google Scholar]
  8. Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S et al. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis 2017; 17:615–625 [View Article][PubMed]
     [Google Scholar]
  9. Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 2017; 11:e0005584 [View Article][PubMed]
     [Google Scholar]
  10. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559–1567 [View Article][PubMed]
     [Google Scholar]
  11. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 2013; 110:E2046E2053 [View Article][PubMed]
     [Google Scholar]
  12. Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 2015; 15:745–759 [View Article][PubMed]
     [Google Scholar]
  13. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182:4865–4873 [View Article][PubMed]
     [Google Scholar]
  14. Katzelnick LC, Coloma J, Harris E. Dengue: knowledge gaps, unmet needs, and research priorities. Lancet Infect Dis 2017; 17:e88-e100 [View Article][PubMed]
     [Google Scholar]
  15. Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J et al. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis 2012; 205:647–655 [View Article][PubMed]
     [Google Scholar]
  16. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 2001; 75:3501–3508 [View Article][PubMed]
     [Google Scholar]
  17. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 2001; 166:1499–1506[PubMed]
     [Google Scholar]
  18. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008; 82:3939–3951 [View Article][PubMed]
     [Google Scholar]
  19. Haruta M, Tomita Y, Yuno A, Matsumura K, Ikeda T et al. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther 2013; 20:504–513 [View Article][PubMed]
     [Google Scholar]
  20. van Helden SF, van Leeuwen FN, Figdor CG. Human and murine model cell lines for dendritic cell biology evaluated. Immunol Lett 2008; 117:191–197 [View Article][PubMed]
     [Google Scholar]
  21. Chase AJ, Medina FA, Muñoz-Jordán JL. Impairment of CD4+ T cell polarization by dengue virus-infected dendritic cells. J Infect Dis 2011; 203:1763–1774 [View Article][PubMed]
     [Google Scholar]
  22. Schmid MA, Harris E. Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog 2014; 10:e1004541 [View Article][PubMed]
     [Google Scholar]
  23. Cerny D, Haniffa M, Shin A, Bigliardi P, Tan BK et al. Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog 2014; 10:e1004548 [View Article][PubMed]
     [Google Scholar]
  24. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663–676 [View Article][PubMed]
     [Google Scholar]
  25. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861–872 [View Article][PubMed]
     [Google Scholar]
  26. Senju S, Haruta M, Matsumura K, Matsunaga Y, Fukushima S et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther 2011; 18:874–883 [View Article][PubMed]
     [Google Scholar]
  27. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 2014; 14:94–108 [View Article][PubMed]
     [Google Scholar]
  28. Goodman AG, Zeng H, Proll SC, Peng X, Cillóniz C et al. The alpha/beta interferon receptor provides protection against influenza virus replication but is dispensable for inflammatory response signaling. J Virol 2010; 84:2027–2037 [View Article][PubMed]
     [Google Scholar]
  29. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006; 25:373–381 [View Article][PubMed]
     [Google Scholar]
  30. Bousso P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat Rev Immunol 2008; 8:675–684 [View Article][PubMed]
     [Google Scholar]
  31. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S et al. and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20:621–667
     [Google Scholar]
  32. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197:823–829 [View Article][PubMed]
     [Google Scholar]
  33. Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013; 122:932–942 [View Article][PubMed]
     [Google Scholar]
  34. Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM. IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 2008; 181:8576–8584 [View Article][PubMed]
     [Google Scholar]
  35. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-γ production by T helper 1 cells. Eur J Immunol 1996; 26:659–668 [View Article][PubMed]
     [Google Scholar]
  36. Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci USA 2003; 100:14333–14338 [View Article][PubMed]
     [Google Scholar]
  37. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 2010; 84:4845–4850 [View Article][PubMed]
     [Google Scholar]
  38. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J et al. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 2000; 74:4957–4966 [View Article][PubMed]
     [Google Scholar]
  39. Vandebriel R, Hoefnagel MM. Dendritic cell-based in vitro assays for vaccine immunogenicity. Hum Vaccin Immunother 2012; 8:1323–1325 [View Article][PubMed]
     [Google Scholar]
  40. Hovden AO, Karlsen M, Jonsson R, Aarstad HJ, Appel S. Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. BMC Immunol 2011; 12:2 [View Article][PubMed]
     [Google Scholar]
  41. Uchida L, Espada-Murao LA, Takamatsu Y, Okamoto K, Hayasaka D et al. The dengue virus conceals double-stranded RNA in the intracellular membrane to escape from an interferon response. Sci Rep 2014; 4:7395 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001119
Loading
iPS cell serves as a source of dendritic cells for in vitro dengue virus infection model
J. Gen. Virol. 99, 1239 (2018); https://doi.org/10.1099/jgv.0.001119
/content/journal/jgv/10.1099/jgv.0.001119
/content/journal/jgv/10.1099/jgv.0.001119
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error